Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Study ID
NCT04922658
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Surufatinib — DRUG
    Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
  • Surufatinib Plus Vinorelbine — DRUG
    Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.

Study Details

A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC

Key Dates

Start date
Jul 1, 2021
Status verified
Feb 2024
Primary completion
Dec 31, 2024
Completion
Jun 30, 2025

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Surufatinib
  • Experimental: Surufatinib plus Vinorelbine

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: up to 12 months ]

Central Contacts

Related Studies